Problem 3 - Brenner and Stevens’ Pharmacology

Question

This orally administered inhibitor of active factor \(\mathrm{X}\) (Stuart factor) is used to prevent and treat DVT

Step-by-Step Solution

Answer

Rivaroxaban (Xarelto) is the drug used.

Step 1: Identify the Context

The question is about a medication that inhibits active factor X, also known as the Stuart factor. This factor is part of the coagulation cascade, which is involved in blood clotting.

Step 2: Recognize Indication of Use

The medication in question is used for the prevention and treatment of Deep Vein Thrombosis (DVT), a condition where blood clots form in deep veins, usually in the legs.

Step 3: Determine the Drug Class

The drug is an 'orally administered inhibitor of active factor X'. These drugs are a class of anticoagulants known as direct oral anticoagulants (DOACs) or direct factor Xa inhibitors.

Step 4: Identify the Common Drugs

Examples of drugs in this category include Rivaroxaban (Xarelto), Apixaban (Eliquis), and Edoxaban (Savaysa). These are well-known factor Xa inhibitors that are taken orally.

Step 5: Select the Appropriate Drug

Rivaroxaban (Xarelto) is one of the most common and fits the description of being an orally administered factor Xa inhibitor used in the treatment and prevention of DVT.

Key Concepts

Anticoagulants

Anticoagulants are medications designed to prevent blood clots from forming. They are crucial in managing conditions where the blood's clotting mechanism could be harmful, such as in atrial fibrillation, heart attacks, and strokes. By interfering with the body's natural coagulation processes, anticoagulants help to reduce the risk of potentially life-threatening clots.

These medicines do not dissolve existing clots but instead prevent new ones from forming and existing ones from getting bigger. This helps lessen complications like heart attacks and strokes.

Some key points about anticoagulants include:

• They can be administered orally or through injections.
• Commonly used anticoagulants include warfarin, heparin, and direct oral anticoagulants like rivaroxaban.
• Patients on anticoagulants need regular monitoring to adjust dosages and ensure safety.

Deep Vein Thrombosis

Deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, typically in the legs. It's a serious condition because the clot can break loose and travel to the lungs, causing a pulmonary embolism. Recognizing and treating DVT promptly is vital to prevent such complications.

Symptoms of DVT can be subtle or quite noticeable. They include swelling, pain, tenderness, and redness in the affected leg. However, some people may not experience any symptoms at all.

To manage DVT, doctors often prescribe anticoagulants to prevent the clot from growing or new clots from forming. Early diagnosis and prompt treatment can reduce risks and lead to better health outcomes.

• Risk factors for DVT include prolonged immobility, surgery, and certain genetic conditions.
• Preventative measures include moving around during long periods of inactivity and wearing compression stockings.

Coagulation Cascade

The coagulation cascade is a series of processes in which blood changes from a liquid to a gel, forming a clot. This cascade involves a complex sequence of events, where each step activates the next one, leading to the formation of a stable blood clot.

Active factor X, also known as the Stuart factor, is central in this cascade. It plays a key role in converting prothrombin into thrombin, which is essential for forming fibrin, the protein threads that stabilize a blood clot.

Factor Xa inhibitors work by targeting this specific stage in the cascade, thus hindering the cascade's progression and preventing clot formation. Understanding the coagulation cascade helps health professionals develop better anticoagulant therapies and manage clotting disorders effectively.

• The cascade involves two pathways: intrinsic and extrinsic, both leading to a common pathway.
• Inhibiting key factors in the cascade, like factor Xa, is how many anticoagulants work to prevent inappropriate clotting.

Direct Oral Anticoagulants

Direct oral anticoagulants (DOACs) are a newer class of anticoagulants that specifically target certain proteins in the coagulation cascade. Unlike older anticoagulants, DOACs provide consistent anticoagulation effects without the need for regular blood monitoring.

DOACs focus on directly inhibiting enzymes like factor Xa, making them effective for both prevention and treatment of clotting disorders such as DVT and pulmonary embolism.

Some benefits of using DOACs include:

• Easier dosing without the need for frequent blood tests.
• Lower risk of dietary interactions compared to warfarin.
• Not requiring routine monitoring of coagulation levels.

Examples of DOACs include rivaroxaban, apixaban, and edoxaban, all of which are taken orally. These medications offer important options for patients in need of effective anticoagulation therapy, especially those unable to follow the stringent monitoring regimes of traditional anticoagulants.